COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,903 Articles (22,568 medRxiv, 8,335 bioRxiv)

Most recent first Previous |  Page 1276: Articles 12751-12760  | Next

Predictive Analysis of COVID-19 Spread in Sri Lanka using an Adaptive Compartmental Model: Susceptible-Exposed-Infected-Recovered-Dead (SEIRD) Model
Rajapaksha, N. U., Wijesinghe, S. D., Jayasooriya, S. P., Weerasinghe, P. C., Gunawardana, I.
10.1101/2021.08.09.21261819 — Posted: 2021-08-10
Using Novel, Agent-Based Periodic Mobility Model with Super Spreaders to Analyze Vaccination Strategies for COVID-19
Jacob, M. K., Guo, E. X.
10.1101/2021.08.09.21261809 — Posted: 2021-08-10
Ignoring spatial heterogeneity in drivers of SARS-CoV-2 transmission in the US will impede sustained elimination
Susswein, Z., Valdano, E., Brett, T., Rohani, P., Colizza, V., Bansal, S.
10.1101/2021.08.09.21261807 — Posted: 2021-08-10
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Gilbert, P. B., Montefiori, D., McDermott, A., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B. C., O'Connell, S., McDanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., Borate, B., van der Laan, L. W. P., Hejazi, N., Huynh, C., Miller, J., El Sahly, H., Baden, L., Baron, M., De La Cruz, L., Gay, C., Kalams, S., Kelley, C. F., Kutner, M., Corey, L., Neuzil, K. M., Carpp, L. N., Pajon, R., Follmann, D., Donis, R. O., Koup, R. A., Immune Assays Team, , Moderna, Inc. Team, , Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, , United States Government (USG)/CoVPN Biostatistics Team
10.1101/2021.08.09.21261290 — Posted: 2021-08-10 Discussion: Onsite
Infected surfaces as a source of transmissible material in healthcare settings dealing with COVID 19 patients
Khedkar, G. D., Bajaj, P., Kalyankar, A., Deolalikar, R., Khilare, V., Khedkar, A., Bajaj, R., Khedkar, C., Prakash, B., Khedkar, C., Chavan, S., Jyosthna, P., Niranjan, V., Jilla, M., Takalkar, U.
10.1101/2021.08.06.21261491 — Posted: 2021-08-10
Antibody mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q
Wilhelm, A., Toptan, T., Pallas, C., Wolf, T., Goetsch, U., Gottschalk, R., Vehreschild, M. J., Ciesek, S., Widera, M.
10.1101/2021.08.09.21261704 — Posted: 2021-08-10 Discussion: Onsite
Impacts of Regional Lockdown Policies on COVID-19 Transmission in India in 2020
Kalra, A., Novosad, P.
10.1101/2021.08.09.21261277 — Posted: 2021-08-10
Use of health care services during the Covid-19 pandemic in Ethiopia: Evidence from a health facility survey
Shuka, Z. S., Mebratie, A. D., Alemu, G., Rieger, M., Bedi, A. S.
10.1101/2021.08.09.21261754 — Posted: 2021-08-10
Progress of the Delta variant and erosion of vaccine effectiveness, a warning from Utah
Keegan, L., Truelove, S. A., Lessler, J.
10.1101/2021.08.09.21261554 — Posted: 2021-08-10
Evaluation of the Liberty16 mobile real time PCR device for use with the SalivaDirect assay for SARS-CoV-2 testing
Yolda-Carr, D., Thammavongsa, D. A., Vega, N., Turner, S. J., Pickering, P. J., Wyllie, A. L.
10.1101/2021.08.08.21261746 — Posted: 2021-08-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).